
Trontinemab: Roche Announces Phase 3 Development Program for the mAb in Adults with Early Alzheimer Disease
Trontinemab, an investigational monoclonal antibody for treatment of early Alzheimer disease (AD), demonstrated dose-dependent, rapid and significant reduction of amyloid plaques in the brain, according to new data from the phase Ib/IIa Brainshuttle AD …